By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Agilis Biotherapeutics 



  New York    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Agilis Biotherapeutics Announces FDA Orphan Drug Designation For The Treatment Of Friedreich’s Ataxia (FA) 8/2/2016 8:55:35 AM
Agilis Biotherapeutics Announces FDA Orphan Drug Designation For The Treatment Of Aromatic L-Amino Acid Decarboxylase Deficiency 6/29/2016 9:29:01 AM
Agilis Biotherapeutics, First Gene Therapy Company Selected For NIH Therapeutics For Rare And Neglected Diseases Program 6/27/2016 10:03:39 AM
Agilis Biotherapeutics Release: Newborn Screening Study For AADC Deficiency Published In Molecular Genetics And Metabolism 6/2/2016 11:37:55 AM
Agilis Biotherapeutics Announces Orphan Designation Approval In Europe For The Treatment Of Angelman Syndrome 5/4/2016 10:55:57 AM
Agilis Biotherapeutics And T-Top Clinical Research Co. Ltd. Enter Into An Agreement For The Development Of Gene Therapy Treatment Of AADC Deficiency 3/22/2016 10:50:55 AM
Agilis Biotherapeutics Sponsors Inaugural Angelman Syndrome Biomarker And Outcome Measures Meeting 3/14/2016 11:06:23 AM
Agilis Biotherapeutics And Waisman Biomanufacturing Enter Into Exclusive Manufacturing Agreement For Friedreich’s Ataxia Gene Therapy 2/18/2016 9:50:49 AM
Agilis Biotherapeutics And National Taiwan University Enter Into Worldwide, Exclusive License Agreement For The Gene Therapy Treatment Of AADC Deficiency 1/28/2016 9:42:41 AM
Agilis Biotherapeutics Names Former H. Lundbeck A/S (LUN.CO) Executive, Christopher J. Silber, MD, As Chief Medical Officer 1/25/2016 7:32:12 AM
123
//-->